

# Luz MartÃ- n-Carbonero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1486397/publications.pdf>

Version: 2024-02-01

86  
papers

4,204  
citations

101543

36  
h-index

110387

64  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3916  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 128-133.	5.8	291
2	Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. <i>Aids</i> , 2009, 23, 689-696.	2.2	250
3	Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 426-431.	2.1	240
4	Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1467-1471.	1.1	197
5	Pegylated IFN- $\alpha$ 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003, 17, 1023-1028.	2.2	183
6	Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 670-676.	4.0	157
7	Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 177-182.	2.1	148
8	Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007, 21, 41-46.	2.2	127
9	Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine. <i>HIV Clinical Trials</i> , 2003, 4, 115-120.	2.0	106
10	Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468.	5.8	96
11	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). <i>Clinical Microbiology and Infection</i> , 2021, 27, 244-252.	6.0	95
12	Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. <i>Aids</i> , 2004, 18, 1737-1740.	2.2	94
13	Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 699-704.	3.0	87
14	Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1673-1686.	3.0	81
15	Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 401-405.	2.1	79
16	Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV-Infected Patients with Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2007, 195, 973-979.	4.0	79
17	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.	2.2	75
18	Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. <i>Aids</i> , 2011, 25, 73-79.	2.2	74

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205.	3.0	70
20	Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients. <i>HIV Clinical Trials</i> , 2004, 5, 201-205.	2.0	66
21	Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. <i>Aids</i> , 2012, 26, 1387-1392.	2.2	64
22	SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. <i>HIV Clinical Trials</i> , 2002, 3, 186-194.	2.0	58
23	Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008, 22, 15-21.	2.2	57
24	Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 65-68.	2.1	56
25	Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients Receiving Anti-HBV Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 842-848.	1.1	55
26	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.	4.0	55
27	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888.	3.0	54
28	Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 557-561.	2.1	53
29	Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. <i>Clinical Infectious Diseases</i> , 2006, 42, 1032-1039.	5.8	51
30	Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. <i>Aids</i> , 2002, 16, 1959-1961.	2.2	51
31	Baseline Serum Hepatitis C Virus (HCV) RNA Level and Response at Week 4 Are the Best Predictors of Relapse After Treatment With Pegylated Interferon Plus Ribavirin in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 439-444.	2.1	43
32	Treatment of Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis. <i>Journal of Infectious Diseases</i> , 2007, 195, 1181-1183.	4.0	42
33	Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 438-443.	2.5	41
34	Emerging drugs for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 1-19.	2.4	41
35	Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families. <i>HIV Clinical Trials</i> , 2002, 3, 304-309.	2.0	40
36	Predictors of selection of K65R. <i>Aids</i> , 2004, 18, 2094-2096.	2.2	36

#	ARTICLE	IF	CITATIONS
37	Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1397-1401.	5.8	35
38	Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 881-886.	1.0	35
39	Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010, 24, 745-753.	2.2	32
40	Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 139-144.	4.0	32
41	Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 Study. <i>PLoS ONE</i> , 2019, 14, e0220272.	2.5	31
42	Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. <i>Aids</i> , 2002, 16, 1423-1425.	2.2	31
43	Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. <i>Aids</i> , 2017, 31, 1253-1260.	2.2	30
44	Treatment of chronic hepatitis C virus infection. <i>Aids</i> , 2003, 17, 751-753.	2.2	29
45	Impact of Antiretroviral Treatment-Related Toxicities on Hospital Admissions in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 825-829.	1.1	29
46	Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). <i>EBioMedicine</i> , 2020, 55, 102779.	6.1	28
47	Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 364-368.	2.1	27
48	Performance of Six Different Ritonavir-Boosted Protease Inhibitor-Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2006, 7, 163-171.	2.0	26
49	Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity. <i>HIV Clinical Trials</i> , 2006, 7, 246-250.	2.0	26
50	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004, 121, 115-118.	2.1	25
51	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588.	2.2	24
52	Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 405-410.	3.0	24
53	Expression profiling of chromatin-modifying enzymes and global DNA methylation in CD4+ T cells from patients with chronic HIV infection at different HIV control and progression states. <i>Clinical Epigenetics</i> , 2018, 10, 20.	4.1	23
54	Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2018, 218, 1531-1540.	4.0	22

#	ARTICLE	IF	CITATIONS
55	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. <i>Scientific Reports</i> , 2019, 9, 5606.	3.3	22
56	Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfecting patients. <i>Scientific Reports</i> , 2020, 10, 11140.	3.3	22
57	Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 738-742.	3.0	22
58	Hepatitis B Virus and HIV Infection. <i>Seminars in Liver Disease</i> , 2012, 32, 114-119.	3.6	19
59	Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 102-109.	2.1	19
60	New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 550-560.	3.1	15
61	Impact of Drug Levels and Baseline Genotype and Phenotype on the Virologic Response to Amprenavir/Ritonavir-Based Salvage Regimens. <i>AIDS Patient Care and STDs</i> , 2004, 18, 1-6.	2.5	14
62	Predicted effect of direct acting antivirals in the current HIV/HCV-coinfecting population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.	1.0	13
63	Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1262-1264.	1.1	13
64	Gynecomastia in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 739-741.	1.1	12
65	Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4421-4423.	3.9	11
66	Rate of Virologic Failure and Selection of Drug Resistance Mutations Using Different Triple Nucleos(t)ide Analogue Combinations in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1231-1235.	1.1	10
67	New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 379-382.	3.0	10
68	Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 383-385.	1.1	9
69	Patients with hepatitis C lost to follow-up: ethical-legal aspects and search results. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 532-537.	0.3	9
70	Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005, 76, 1-6.	5.0	8
71	Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2005, 19, 621-623.	2.2	8
72	Short Communication: p21/CDKN1A Expression Shows Broad Interindividual Diversity in a Subset of HIV-1 Elite Controllers. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 232-236.	1.1	8

#	ARTICLE	IF	CITATIONS
73	Normalization of liver enzymes in an HIV+hepatitis C virus-co-infected patient after potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1193.	2.2	7
74	Factors associated with the number of drugs in darunavir/cobicistat regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 208-214.	3.0	4
75	Motivo de ingreso hospitalario en pacientes con infección por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. <i>Medicina Clínica</i> , 2002, 119, 293-295.	0.6	3
76	Impact of Hepatitis C Virus (HCV) on Morbidity and Mortality Rates among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2003, 37, 460-461.	5.8	3
77	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2831-2842.	1.8	2
78	Long-Term Use of Atazanavir in the Treatment of HIV-Infected patients. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S5764.	0.4	2
79	Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients. <i>Biomedicines</i> , 2021, 9, 1627.	3.2	2
80	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, 40, 121-124.	0.5	2
81	Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance. <i>Journal of Clinical Medicine</i> , 2022, 11, 3579.	2.4	2
82	Management and therapy of chronic hepatitis C in HIV. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 482-488.	3.8	1
83	HCV and HIV Coinfection. <i>Current Hepatitis Reports</i> , 2011, 10, 52-61.	0.3	1
84	Both Hepatitis C Virus-Specific T Cell Responses and IL28B Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 278-286.	1.2	1
85	Abacavir/lamivudina + atazanavir no potenciado en la práctica clínica diaria: doce años de experiencia. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 29-33.	0.5	0
86	Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 367-372.	0.5	0